Homocysteine and arterial thrombosis: Challenge and opportunity

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245

Hot topics in Cardiovascular Cell and Pharmacotherapy (Part 2)

Issue: 2010: 103/5 (May) pp. 875–1108
Pages: 942-961
Ahead of Print: ###MANUSCRIPT_aheadofprint###

Homocysteine and arterial thrombosis: Challenge and opportunity

M. N. D. Di Minno (1), E. Tremoli (2), A. Coppola (1), R. Lupoli (1), G. Di Minno (1)

(1) Department of Experimental and Clinical Medicine, “Federico II” University, Naples, Italy; (2) Department of Pharmacological Sciences, Milan University, Milan, Italy


homocysteine, folate, Arterial thrombosis


The correlation between homocysteine and vascular disease has been assessed in several clinical studies that demonstrated that elevation of plasma total homocysteine (tHcy) was an independent risk factor for atheriosclerotic disease. Major advances of homocysteine metabolism disorders have been made during the last few years, encompassing the rare homozygous enzyme deficiencies, as well as more common milder abnormalities. In experimental and clinical studies, a homocysteine-mediated oxidant stress has been shown to trigger platelet activation, in turn leading to a tendency to thrombosis, in patients with severe hyperhomocysteinaemia. Likewise, the hypomethylation hypothesis on acquired hyperhomocysteinaemia (chronic renal disease) and the interrelationship between hyperhomocysteinaemia and impaired fibrinolysis, have added further biological plausibility to the role for hyperhomocysteinaemia in vascular medicine. However, whether hyperhomocysteinaemia is causal or a marker of vascular disease, and whether plasma tHcy is only an indicator of the metabolic status remains to be clarified. The role of the intake of some vitamins (folic acid, vit.B12, vit.B6) on cardiovascular disease (CVD) is poorly understood: in spite of the lowering of homocysteine (Hcy) levels, vitamin supplementation failed to exert significant effects on cardiovascular risk. On the other hand, although some lipid-modifying treatments increase Hcy levels in diabetics, there is no evidence that this attenuates the beneficial effects of such treatments on the cardiovascular risk. Because of these uncertainties in the area, the data available do not provide support for routine screening and treatment for elevated Hcy to prevent CVD.

You may also be interested in...

Paolo Bosco 1 , Rosa-Maria Guéant-Rodriguez2 , Guido Anello1 , Rosario Spada 1 , Antonino Romano1,3, Adrian Fajardo1 , Filippo Caraci4 , Raffaele Ferri1 , Jean-Louis Guéant2

Thromb Haemost 2006 96 2: 154-159

Anetta Undas 1, Ewa Stępień 1, Rafal Glowacki 2, Joanna Tisończyk 3, Wieslawa Tracz 1, Hieronim Jakubowski 4, 5

Thromb Haemost 2006 96 3: 342-347


M. Sartori (1), E. Favaretto (1), C. Legnani (1), M. Cini (1), E. Conti (1), A. Amato (1), G. Palareti (1)

Thromb Haemost 2010 104 1: 71-77

Thrombosis News

Mobile technology identifies people with unknown atrial fibrillation at high risk of stroke – article published in Thrombosis and Haemostasis

The article “Feasibility and cost effectiveness of stroke prevention through community screening...

TH 111.4

The April 2014 TH 111.4 issue of Thrombosis and Haemostasis is a Theme Issue by Guest Editor B....

TH 111.3

Women with atrial fibrillation have a much higher risk for thromboembolic stroke than men suffering...